{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T16:07:25Z","timestamp":1770739645020,"version":"3.49.0"},"reference-count":29,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.clgc.2025.102441","type":"journal-article","created":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T08:53:48Z","timestamp":1758704028000},"page":"102441","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prognostic Impact of Biopsy Gleason 4 + 5, 5 + 4, and 5 + 5 in Grade Group 5 after Radical Prostatectomy"],"prefix":"10.1016","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1633-784X","authenticated-orcid":false,"given":"Yu","family":"Ozawa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7213-8816","authenticated-orcid":false,"given":"Rohan","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcio Covas","family":"Moschovas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1422-5695","authenticated-orcid":false,"given":"Marco","family":"Sandri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shady","family":"Saikali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ari","family":"Diamond","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Travis","family":"Rogers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vipul","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.clgc.2025.102441_bib0001","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1590\/s1677-5538.ibju.2023.0530","article-title":"Impacts on functional and oncological outcomes of robotic-assisted radical prostatectomy 10 years after the US Preventive Service Taskforce recommendations against PSA screening","volume":"50","author":"Moschovas","year":"2024","journal-title":"Int Braz J Urol"},{"issue":"2","key":"10.1016\/j.clgc.2025.102441_bib0002","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1002\/pros.24261","article-title":"Effects of the 2012 and 2018 US preventive services task force prostate cancer screening guidelines on pathologic outcomes after prostatectomy","volume":"82","author":"Plambeck","year":"2022","journal-title":"Prostate"},{"issue":"3","key":"10.1016\/j.clgc.2025.102441_bib0003","article-title":"Trends in incidence of metastatic prostate cancer in the US","volume":"5","author":"Desai","year":"2022","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.clgc.2025.102441_bib0004","doi-asserted-by":"crossref","first-page":"423","DOI":"10.4111\/icu.2017.58.6.423","article-title":"US Preventive Services Task Force prostate-specific antigen screening guidelines result in higher Gleason score diagnoses","volume":"58","author":"Gejerman","year":"2017","journal-title":"Investig Clin Urol"},{"issue":"1","key":"10.1016\/j.clgc.2025.102441_bib0005","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.pathol.2020.09.016","article-title":"Gleason grade 5 prostate cancer: sub-patterns and prognosis","volume":"53","author":"Atallah","year":"2021","journal-title":"Pathology"},{"issue":"2","key":"10.1016\/j.clgc.2025.102441_bib0006","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.euf.2020.01.008","article-title":"The significance of primary biopsy Gleason 5 in patients with grade group 5 prostate cancer","volume":"6","author":"Tilki","year":"2020","journal-title":"Eur Urol Focus"},{"issue":"3","key":"10.1016\/j.clgc.2025.102441_bib0007","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/j.euf.2021.04.011","article-title":"Pattern of biopsy Gleason grade group 5 (4 + 5 vs 5 + 4 vs 5 + 5) predicts survival after radical prostatectomy or external beam radiation therapy","volume":"8","author":"Wenzel","year":"2022","journal-title":"Eur Urol Focus"},{"issue":"2","key":"10.1016\/j.clgc.2025.102441_bib0008","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.euo.2023.11.002","article-title":"Prognosis of Gleason score 9-10 prostatic adenocarcinoma in needle biopsies: a nationwide population-based study","volume":"7","author":"Egevad","year":"2024","journal-title":"Eur Urol Oncol"},{"issue":"2","key":"10.1016\/j.clgc.2025.102441_bib0009","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1097\/PAS.0000000000000530","article-title":"The 2014 international society of urological pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma: definition of grading patterns and proposal for a new grading system","volume":"40","author":"Epstein","year":"2016","journal-title":"Am J Surg Pathol"},{"issue":"8","key":"10.1016\/j.clgc.2025.102441_bib0010","doi-asserted-by":"crossref","first-page":"e87","DOI":"10.1097\/PAS.0000000000001497","article-title":"The 2019 International Society of Urological Pathology (ISUP) consensus conference on grading of prostatic carcinoma","volume":"44","author":"van Leenders","year":"2020","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.clgc.2025.102441_bib0011","unstructured":"National Comprehensive Cancer Network (NCCN):NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae): Prostate Cancer. Version 1.2025. Available at: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/prostate.pdf. Accessed May 7, 2025."},{"issue":"3","key":"10.1016\/j.clgc.2025.102441_bib0012","first-page":"245","article-title":"Prostate cancer-major changes in the American Joint Committee on Cancer eighth edition cancer staging manual","volume":"67","author":"Buyyounouski","year":"2017","journal-title":"CA Cancer J Clin"},{"issue":"6","key":"10.1016\/j.clgc.2025.102441_bib0013","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/j.eururo.2020.05.041","article-title":"Modified apical dissection and lateral prostatic fascia preservation improves early postoperative functional recovery in robotic-assisted laparoscopic radical prostatectomy: results from a propensity score-matched analysis","volume":"78","author":"Covas Moschovas","year":"2020","journal-title":"Eur Urol"},{"issue":"9","key":"10.1016\/j.clgc.2025.102441_bib0014","doi-asserted-by":"crossref","first-page":"3127","DOI":"10.1245\/s10434-013-2996-4","article-title":"Gleason 5+4 has worse oncological and pathological outcomes compared with Gleason 4+5: significance of Gleason 5 pattern","volume":"20","author":"Lim","year":"2013","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"10.1016\/j.clgc.2025.102441_bib0015","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.eururo.2018.12.014","article-title":"Guidelines for reporting of statistics for clinical research in urology","volume":"75","author":"Assel","year":"2019","journal-title":"Eur Urol"},{"issue":"2","key":"10.1016\/j.clgc.2025.102441_bib0016","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.euo.2021.01.001","article-title":"Management of persistently elevated prostate-specific antigen after radical prostatectomy: a systematic review of the literature","volume":"4","author":"Ploussard","year":"2021","journal-title":"Eur Urol Oncol"},{"issue":"9","key":"10.1016\/j.clgc.2025.102441_bib0017","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.urolonc.2016.04.002","article-title":"Racial\/ethnic differences in the relative risk of receipt of specific treatment among men with prostate cancer","volume":"34","author":"Moses","year":"2016","journal-title":"Urol Oncol"},{"issue":"5","key":"10.1016\/j.clgc.2025.102441_bib0018","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1016\/S0022-5347(05)64280-2","article-title":"Percentage of positive biopsy cores as predictor of clinical outcome in prostate cancer treated with radiotherapy","volume":"168","author":"Kestin","year":"2002","journal-title":"J Urol"},{"issue":"12","key":"10.1016\/j.clgc.2025.102441_bib0019","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/s41585-021-00514-9","article-title":"Neoadjuvant hormonal therapy before radical prostatectomy in high-risk prostate cancer","volume":"18","author":"Devos","year":"2021","journal-title":"Nat Rev Urol"},{"issue":"11","key":"10.1016\/j.clgc.2025.102441_bib0020","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1038\/s41585-021-00497-7","article-title":"Salvage therapy for prostate cancer after radical prostatectomy","volume":"18","author":"Zaorsky","year":"2021","journal-title":"Nat Rev Urol"},{"issue":"40","key":"10.1016\/j.clgc.2025.102441_bib0021","first-page":"1","article-title":"Recent advances in the management of high-risk localized prostate cancer: local therapy, systemic therapy, and biomarkers to guide treatment decisions","volume":"40","author":"McKay","year":"2020","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"9","key":"10.1016\/j.clgc.2025.102441_bib0022","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1377\/hlthaff.2020.00284","volume":"39","author":"Buxbaum","year":"2020","journal-title":"Health Aff (Millwood)"},{"issue":"5","key":"10.1016\/j.clgc.2025.102441_bib0023","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.eururo.2020.01.033","article-title":"Benefits and risks of primary treatments for high-risk localized and locally advanced prostate cancer: an international multidisciplinary systematic review","volume":"77","author":"Moris","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2025.102441_bib0024","unstructured":"EAU Guidelines. Edn. Presented at the EAU Annual Congress Madrid 2025. Available from: https:\/\/uroweb.org\/guidelines. Accessed March 27, 2025."},{"issue":"19","key":"10.1016\/j.clgc.2025.102441_bib0025","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1056\/NEJMoa1801993","article-title":"MRI-targeted or standard biopsy for prostate-cancer diagnosis","volume":"378","author":"Kasivisvanathan","year":"2018","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.clgc.2025.102441_bib0026","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1056\/NEJMoa1910038","article-title":"MRI-targeted, systematic, and combined biopsy for prostate cancer diagnosis","volume":"382","author":"Ahdoot","year":"2020","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.clgc.2025.102441_bib0027","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s00428-017-2241-9","article-title":"Evaluation of tumor morphologies and association with biochemical recurrence after radical prostatectomy in grade group 5 prostate cancer","volume":"472","author":"Flood","year":"2018","journal-title":"Virchows Arch"},{"issue":"7","key":"10.1016\/j.clgc.2025.102441_bib0028","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1111\/his.14901","article-title":"Cribriform morphology is associated with higher risk of biochemical recurrence after radical prostatectomy in patients with grade Group 5 prostate cancer","volume":"82","author":"Oufattole","year":"2023","journal-title":"Histopathology"},{"issue":"2","key":"10.1016\/j.clgc.2025.102441_bib0029","doi-asserted-by":"crossref","first-page":"218","DOI":"10.7326\/ANNALS-24-00700","article-title":"Impact of genomic classifiers on risk stratification and treatment intensity in patients with localized prostate cancer : a systematic review","volume":"178","author":"Tabriz","year":"2025","journal-title":"Ann Intern Med"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767325001417?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767325001417?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T21:08:59Z","timestamp":1770671339000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767325001417"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":29,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S1558767325001417"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2025.102441","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prognostic Impact of Biopsy Gleason 4 + 5, 5 + 4, and 5 + 5 in Grade Group 5 after Radical Prostatectomy","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2025.102441","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102441"}}